nach oben

The European Journal of Health Economics

Erschienen in:

23.02.2016 | Original Paper

Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany

verfasst von: Alexander Kuhlmann, J.-Matthias Graf von der Schulenburg

Erschienen in: The European Journal of Health Economics | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

In 2009, the European Medicines Agency granted approval for two higher-valent pneumococcal conjugate vaccines. This study aims to evaluate the cost-effectiveness of universal infant (<2 years old) vaccination with a 13-valent pneumococcal conjugate vaccine (PCV13) in comparison with a 10-valent pneumococcal conjugate vaccine (PCV10) for the prevention of pneumococcal disease in Germany.

Methods

A population-based Markov model was developed to estimate the impact of PCV13 and PCV10 on invasive pneumococcal disease (IPD), non-invasive pneumonia (PNE), and acute otitis media (AOM) over a time horizon of 50 years. The model included the effects of the historical vaccination scheme in infants as well as indirect herd effects and replacement disease. We used German epidemiological data to calculate episodes of IPD, PNE, and AOM, as well as direct and indirect effects of the vaccination. Parameter uncertainty was tested in univariate and probabilistic sensitivity analyses.

Results

In the base-case analysis, the ICER of PCV13 versus PCV10 infant vaccination was EUR 9826 per quality-adjusted life-year (QALY) gained or EUR 5490 per life-year (LY) gained from the societal perspective and EUR 3368 per QALY gained or EUR 1882 per LY gained from the perspective of the German statutory health insurance. The results were particularly sensitive to the magnitude of indirect effects of both vaccines.

Conclusions

Universal infant vaccination with PCV13 is likely to be a cost-effective intervention compared with PCV10 within the German health care system, if additional net indirect effects of PCV13 vaccination are significant.

Nur mit Berechtigung zugänglich

World Health Organization: Pneumococcal conjugate vaccine for childhood immunization: WHO position paper. Wkly Epidemiol. Rec. 82(12), 93–104 (2007)

O’Brien, K.L., Wolfson, L.J., Watt, J.P., Henkle, E., Deloria-Knoll, M., McCall, N., Lee, E., Mulholland, K., Levine, O.S., Cherian, T.: Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374(9693), 893–902 (2009). doi:10.1016/S0140-6736(09)61204-6 CrossRefPubMed

Robert Koch-Institut: Zu den Neuerungen in den Impfempfehlungen der STIKO. Epidemiol. Bull. 29, 219–233 (2001)

Robert Koch-Institut: Neuerungen in den aktuellen Empfehlungen der Ständigen Impfkommission (STIKO) am RKI vom Juli 2006. Epidemiol. Bull. 32, 271–280 (2006)

Rückinger, S., van der Linden, M., Reinert, R.R., von Kries, R., Burckhardt, F., Siedler, A.: Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. Vaccine 27(31), 4136–4141 (2009). doi:10.1016/j.vaccine.2009.04.057 CrossRefPubMed

van der Linden, M., Weiß, S., Falkenhorst, G., Siedler, A., Imöhl, M., von Kries, R.: Four years of universal pneumococcal conjugate infant vaccination in Germany: impact on incidence of invasive pneumococcal disease and serotype distribution in children. Vaccine 30(40), 5880–5885 (2012). doi:10.1016/j.vaccine.2012.06.068 CrossRefPubMed

Imöhl, M., Reinert, R.R., van der Linden, M.: Temporal variations among invasive pneumococcal disease serotypes in children and adults in Germany (1992–2008). Int. J. Microbiol. 2010, 874189 (2010). doi:10.1155/2010/874189 CrossRefPubMedPubMedCentral

Robert Koch-Insitut: Pneumoweb

Nationales Referenzzentrum für Streptokokken: Distribution of serotypes in invasive pneumococcal disease. Data on file (2013)

10.

Bialkowski, A., Gärtner, J., Giani, G., Haas, W., Henneke, P., Jakob, A., Kölker, S., Kries, R. von, Liese, J., Poets, C.-F., Schaible, T., Wabitsch, M.: ESPED-Jahresbericht (2013)

11.

Chuck, A.W., Jacobs, P., Tyrrell, G., Kellner, J.D.: Pharmacoeconomic evaluation of 10- and 13-valent pneumococcal conjugate vaccines. Vaccine 28(33), 5485–5490 (2010). doi:10.1016/j.vaccine.2010.05.058 CrossRefPubMed

12.

Kim, S.-Y., Lee, G., Goldie, S.J.: Economic evaluation of pneumococcal conjugate vaccination in the Gambia. BMC Infect. Dis. 10, 260 (2010). doi:10.1186/1471-2334-10-260 CrossRefPubMedPubMedCentral

13.

Urueña, A., Pippo, T., Betelu, M.S., Virgilio, F., Giglio, N., Gentile, A., Jimenez, S.G., Jáuregui, B., Clark, A.D., Diosque, M., Vizzotti, C.: Cost-effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina. Vaccine 29(31), 4963–4972 (2011). doi:10.1016/j.vaccine.2011.04.111 CrossRefPubMed

14.

Newall, A.T., Creighton, P., Philp, D.J., Wood, J.G., MacIntyre, C.R.: The potential cost-effectiveness of infant pneumococcal vaccines in Australia. Vaccine 29(45), 8077–8085 (2011). doi:10.1016/j.vaccine.2011.08.050 CrossRefPubMed

15.

Robberstad, B., Frostad, C.R., Akselsen, P.E., Kværner, K.J., Berstad, A.K.: Economic evaluation of second-generation pneumococcal conjugate vaccines in Norway. Vaccine 29(47), 8564–8574 (2011). doi:10.1016/j.vaccine.2011.09.025 CrossRefPubMed

16.

Tyo, K.R., Rosen, M.M., Zeng, W., Yap, M., Pwee, K.H., Ang, L.W., Shepard, D.S.: Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines. Vaccine 29(38), 6686–6694 (2011). doi:10.1016/j.vaccine.2011.06.091 CrossRefPubMed

17.

Rozenbaum, M.H., Sanders, E.A.M., van Hoek, A.J., van der Jansen, A.G.S.C., Ende, A., van den Dobbelsteen, G., Rodenburg, G.D., Hak, E., Postma, M.J.: Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ 340, c2509 (2010)CrossRefPubMed

18.

Strutton, D.R., Farkouh, R.A., Earnshaw, S.R., Hwang, S., Theidel, U., Kontodimas, S., Klok, R., Papanicolaou, S.: Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands. J. Infect. 64(1), 54–67 (2012). doi:10.1016/j.jinf.2011.10.015 CrossRefPubMed

19.

Knerer, G., Ismaila, A., Pearce, D.: Health and economic impact of PHiD-CV in Canada and the UK: a Markov modelling exercise. J. Med. Econ. 15(1), 61–76 (2012). doi:10.3111/13696998.2011.622323 CrossRefPubMed

20.

Bakır, M., Türel, Ö., Topachevskyi, O.: Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey: a decision analytical model. BMC Health Serv. Res. 12(1), 386 (2012). doi:10.1186/1472-6963-12-386 CrossRefPubMedPubMedCentral

21.

Earnshaw, S.R., McDade, C.L., Zanotti, G., Farkouh, R.A., Strutton, D.: Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada. BMC Infect. Dis. 12(1), 101 (2012). doi:10.1186/1471-2334-12-101 CrossRefPubMedPubMedCentral

22.

Gomez, J.A., Tirado, J.C., Rojas, A.A.N., Alba, M.M.C., Topachevskyi, O.: Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru. BMC Public Health 13, 1025 (2013). doi:10.1186/1471-2458-13-1025 CrossRefPubMedPubMedCentral

23.

Klok, R.M., Lindkvist, R.-M., Ekelund, M., Farkouh, R.A., Strutton, D.R.: Cost-effectiveness of a 10-versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden. Clin. Therap. 35(2), 119–134 (2013). doi:10.1016/j.clinthera.2012.12.006 CrossRef

24.

Vučina, V.V., Filipović, S.K., Kožnjak, N., Stamenić, V., Clark, A.D., Mounaud, B., Blau, J., Hoestlandt, C., Kaić, B.: Cost-effectiveness of pneumococcal conjugate vaccination in Croatia. Vaccine 33(Suppl 1), A209–A218 (2015). doi:10.1016/j.vaccine.2014.12.043 PubMed

25.

Mezones-Holguin, E., Canelo-Aybar, C., Clark, A.D., Janusz, C.B., Jaúregui, B., Escobedo-Palza, S., Hernandez, A.V., Vega-Porras, D., González, M., Fiestas, F., Toledo, W., Michel, F., Suárez, V.J.: Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru. Vaccine 33(Suppl 1), A154–A166 (2015). doi:10.1016/j.vaccine.2014.12.039 CrossRefPubMed

26.

Kieninger, M.P., Caballero, E.G., Sosa, A.A., Amarilla, C.T., Jáuregui, B., Janusz, C.B., Clark, A.D., Castellanos, R.M.: Cost-effectiveness analysis of pneumococcal conjugate vaccine introduction in Paraguay. Vaccine 33(Suppl 1), A143–A153 (2015). doi:10.1016/j.vaccine.2014.12.078 CrossRefPubMed

27.

Ordóñez, J.E., Orozco, J.J.: Cost-effectiveness analysis of the available pneumococcal conjugated vaccines for children under 5 years in Colombia. Cost Eff. Resour. Alloc. 13, 6 (2015). doi:10.1186/s12962-015-0032-1 CrossRefPubMedPubMedCentral

28.

Vemer, P., Postma, M.J.: A few years later. Update of the cost-effectiveness of infant pneumococcal vaccination in Dutch children. Hum. Vaccines Immunother. 10(7), 1841–1849 (2014). doi:10.4161/hv.29008 CrossRef

29.

Ayieko, P., Griffiths, U.K., Ndiritu, M., Moisi, J., Mugoya, I.K., Kamau, T., English, M., Scott, J.A.G.: Assessment of health benefits and cost-effectiveness of 10-valent and 13-valent pneumococcal conjugate vaccination in Kenyan children. PLoS One 8(6), e67324 (2013). doi:10.1371/journal.pone.0067324 CrossRefPubMedPubMedCentral

30.

Shiragami, M., Mizukami, A., Leeuwenkamp, O., Mrkvan, T., Delgleize, E., Kurono, Y., Iwata, S.: Cost-effectiveness evaluation of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine and 13-valent pneumococcal vaccine in Japanese children. Infect. Dis. Ther. (2014). doi:10.1007/s40121-014-0053-7 PubMedPubMedCentral

31.

Siebert, U., Alagoz, O., Bayoumi, A.M., Jahn, B., Owens, D.K., Cohen, D.J., Kuntz, K.M.: State-transition modeling: a report of the ISPOR-SMDM modeling good research practices task force-3. Value Health 15(6), 812–820 (2012). doi:10.1016/j.jval.2012.06.014 CrossRefPubMed

32.

Gray, A.: Applied methods of cost-effectiveness analysis in health care. Handbooks in health economic evaluation series. Oxford University Press, Oxford (2011)

33.

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG): General methods for evaluating the relation between cost and benefit—version 1.0 general methods for evaluating the relation between cost and benefit—version 1.0 (2009)

34.

Bowles, D., Zuchandke, A.: Entwicklung eines Modells zur Bevölkerungsprojektion—Modellrechnungen zur Bevölkerungsentwicklung bis 2060 (2012)

35.

Göbel, U., Heinrich, B., Krauth, K.A., Steingrüber, H.-J., von Kries, R.: Evaluation der Prozess- und Ergebnisqualität der Erhebungseinheit für seltene pädiatrische Erkrankungen in Deutschland (ESPED) (Process and outcome quality of the German Paediatric Surveillance Unit (ESPED)). Klin. Padiatr. 222(2), 92–97 (2010). doi:10.1055/s-0030-1247587 CrossRefPubMed

36.

von Kries, R., Toschke, A.M., Siedler, A.: Population-based Nationwide Study on Invasive Pneumococcal Infections among Children in Germany (1997–2003) (unpublished)

37.

Reinert, R.R., Haupts, S., van der Linden, M., Heeg, C., Cil, M.Y., Al-Lahham, A., Fedson, D.S.: Invasive pneumococcal disease in adults in North-Rhine Westphalia, Germany, 2001–2003. Clin. Microbiol. Infect. 11(12), 985–991 (2005). doi:10.1111/j.1469-0691.2005.01282.x CrossRefPubMed

38.

Rüggeberg, J.U., Ketteler, K., MacKenzie, C.R., von Kries, R., Reinert, R.R., Schroten, H.: Blood culture sampling rates at a German pediatric university hospital and incidence of invasive pneumococcal disease. Infection 32(2), 78–81 (2004). doi:10.1007/s15010-004-3104-2 CrossRefPubMed

39.

Federal Statistical Office of Germany (Statistisches Bundesamt): Diagnosedaten der Krankenhäuser ab 2000 (2013)

40.

IMS Health Deutschland: Verschreibungsindex für Pharmazeutika (VIP) (unpublished) (2009)

41.

Schnoor, M., Hedicke, J., Dalhoff, K., Raspe, H., Schäfer, T.: Approaches to estimate the population-based incidence of community acquired pneumonia. J. Infect. 55(3), 233–239 (2007). doi:10.1016/j.jinf.2007.04.355 CrossRefPubMed

42.

Schnabel, E., Sausenthaler, S., Brockow, I., Liese, J., Herbarth, O., Michael, B., Schaaf, B., Krämer, U., von Berg, A., Wichmann, H.-E., Heinrich, J.: Burden of otitis media and pneumonia in children up to 6 years of age: results of the LISA birth cohort. Eur. J. Pediatr. 168(10), 1251–1257 (2009). doi:10.1007/s00431-008-0921-9 CrossRefPubMed

43.

Grüber, C., Keil, T., Kulig, M., Roll, S., Wahn, U., Wahn, V.: History of respiratory infections in the first 12 years among children from a birth cohort. Pediatr. Allergy Immunol. 19(6), 505–512 (2008). doi:10.1111/j.1399-3038.2007.00688.x CrossRefPubMed

44.

Kamtsiuris, P., Atzpodien, K., Ellert, U., Schlack, R., Schlaud, M.: Prävalenz von somatischen Erkrankungen bei Kindern und Jugendlichen in Deutschland. Ergebnisse des Kinder- und Jugendgesundheitssurveys (KiGGS) (Prevalence of somatic diseases in German children and adolescents. Results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS)). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 50(5–6), 686–700 (2007). doi:10.1007/s00103-007-0230-x CrossRefPubMed

45.

Kværner, K.J., Kristiansen, H.A., Russell, M.B.: Otitis media history, surgery and allergy in 60-year perspective: a population-based study. Int. J. Pediatr. Otorhinolaryngol. 74(12), 1356–1360 (2010). doi:10.1016/j.ijporl.2010.09.002 CrossRefPubMed

46.

Pang, L.H., Barakate, M.S., Havas, T.E.: Mastoiditis in a paediatric population: a review of 11 years experience in management. Int. J. Pediatr. Otorhinolaryngol. 73(11), 1520–1524 (2009). doi:10.1016/j.ijporl.2009.07.003 CrossRefPubMed

47.

van Hoek, A.J., Andrews, N., Waight, P.A., Stowe, J., Gates, P., George, R., Miller, E.: The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J. Infect. 65(1), 17–24 (2012). doi:10.1016/j.jinf.2012.02.017 CrossRefPubMed

48.

Poethko-Müller, C., Kuhnert, R., Schlaud, M.: Durchimpfung und Determinanten des Impfstatus in Deutschland. Ergebnisse des Kinder- und Jugendgesundheitssurveys (KiGGS) (Vaccination coverage and predictors for vaccination level. Results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS)). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 50(5–6), 851–862 (2007). doi:10.1007/s00103-007-0248-0 CrossRefPubMed

49.

Bader, H.-M.: Impfschutz in Schleswig-Holstein 2011 (2013)

50.

Rieck, T.: Impfquoten aus KV-Daten - Sinnvolle Ergänzung zu den Schuleingangsuntersuchungen (2013)

51.

Black, S., Shinefield, H., Fireman, B., Lewis, E., Ray, P., Hansen, J.R., Elvin, L., Ensor, K.M., Hackell, J., Siber, G., Malinoski, F., Madore, D., Chang, I., Kohberger, R., Watson, W., Austrian, R., Edwards, K.: Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr. Infect. Dis. J. 19(3), 187–195 (2000)CrossRefPubMed

52.

Palmu, A.A., Jokinen, J., Borys, D., Nieminen, H., Ruokokoski, E., Siira, L., Puumalainen, T., Lommel, P., Hezareh, M., Moreira, M., Schuerman, L., Kilpi, T.M.: Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease. A cluster randomised trial. Lancet 381(9862), 214–222 (2013). doi:10.1016/S0140-6736(12)61854-6 CrossRefPubMed

53.

Hansen, J., Black, S., Shinefield, H., Cherian, T., Benson, J., Fireman, B., Lewis, E., Ray, P., Lee, J.: Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr. Infect. Dis. J. 25(9), 779–781 (2006). doi:10.1097/01.inf.0000232706.35674.2f CrossRefPubMed

54.

Tregnaghi, M.W., Sáez-Llorens, X., López, P., Abate, H., Smith, E., Pósleman, A., Calvo, A., Wong, D., Cortes-Barbosa, C., Ceballos, A., Tregnaghi, M., Sierra, A., Rodriguez, M., Troitiño, M., Carabajal, C., Falaschi, A., Leandro, A., Castrejón, M.M., Lepetic, A., Lommel, P., Hausdorff, W.P., Borys, D., Ruiz Guiñazú, J., Ortega-Barría, E., Yarzábal, J.P., Schuerman, L.: Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: a double-blind randomized controlled trial. PLoS Med. 11(6), e1001657 (2014). doi:10.1371/journal.pmed.1001657 CrossRefPubMedPubMedCentral

55.

Black, S.B., Shinefield, H.R., Ling, S., Hansen, J., Fireman, B., Spring, D., Noyes, J., Lewis, E., Ray, P., Lee, J., Hackell, J.: Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr. Infect. Dis. J. 21(9), 810–815 (2002). doi:10.1097/01.inf.0000027926.99356.4c CrossRefPubMed

56.

Taylor, S., Marchisio, P., Vergison, A., Harriague, J., Hausdorff, W.P., Haggard, M.: Impact of pneumococcal conjugate vaccination on otitis media: a systematic review. Clin. Infect. Dis. 54(12), 1765–1773 (2012). doi:10.1093/cid/cis292 CrossRefPubMedPubMedCentral

57.

Black, S., Shinefield, H.: Safety and efficacy of the seven-valent pneumococcal conjugate vaccine: evidence from Northern California. Eur. J. Pediatr. 161(Suppl 2), S127–S131 (2002). doi:10.1007/s00431-002-1064-z CrossRefPubMed

58.

Fireman, B., Black, S.B., Shinefield, H.R., Lee, J., Lewis, E., Ray, P.: Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr. Infect. Dis. J. 22(1), 10–16 (2003). doi:10.1097/01.inf.0000045221.96634.7c CrossRefPubMed

59.

Eskola, J., Kilpi, T., Palmu, A., Jokinen, J., Haapakoski, J., Herva, E., Takala, A., Käyhty, H., Karma, P., Kohberger, R., Siber, G., Mäkelä, P.H.: Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N. Engl. J. Med. 344(6), 403–409 (2001). doi:10.1056/NEJM200102083440602 CrossRefPubMed

60.

O’Brien, K.L., David, A.B., Chandran, A., Moulton, L.H., Reid, R., Weatherholtz, R., Santosham, M.: Randomized, controlled trial efficacy of pneumococcal conjugate vaccine against otitis media among Navajo and White Mountain Apache infants. Pediatr. Infect. Dis. J. 27(1), 71–73 (2008). doi:10.1097/INF.0b013e318159228f CrossRefPubMed

61.

Prymula, R., Peeters, P., Chrobok, V., Kriz, P., Novakova, E., Kaliskova, E., Kohl, I., Lommel, P., Poolman, J., Prieels, J.-P., Schuerman, L.: Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 367(9512), 740–748 (2006). doi:10.1016/S0140-6736(06)68304-9 CrossRefPubMed

62.

63.

Melegaro, A., Choi, Y.H., George, R., Edmunds, W.J., Miller, E., Gay, N.J.: Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease. BMC Infect. Dis. 10, 90 (2010). doi:10.1186/1471-2334-10-90 CrossRefPubMedPubMedCentral

64.

Whitney, C.G., Farley, M.M., Hadler, J., Harrison, L.H., Bennett, N.M., Lynfield, R., Reingold, A., Cieslak, P.R., Pilishvili, T., Jackson, D., Facklam, R.R., Jorgensen, J.H., Schuchat, A.: Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 348(18), 1737–1746 (2003). doi:10.1056/NEJMoa022823 CrossRefPubMed

65.

Lexau, C.A., Lynfield, R., Danila, R., Pilishvili, T., Facklam, R., Farley, M.M., Harrison, L.H., Schaffner, W., Reingold, A., Bennett, N.M., Hadler, J., Cieslak, P.R., Whitney, C.G.: Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 294(16), 2043–2051 (2005). doi:10.1001/jama.294.16.2043 CrossRefPubMed

66.

Grijalva, C.G., Poehling, K.A., Nuorti, J.P., Zhu, Y., Martin, S.W., Edwards, K.M., Griffin, M.R.: National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics 118(3), 865–873 (2006). doi:10.1542/peds.2006-0492 CrossRefPubMed

67.

Grijalva, C.G., Nuorti, J.P., Arbogast, P.G., Martin, S.W., Edwards, K.M., Griffin, M.R.: Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 369(9568), 1179–1186 (2007). doi:10.1016/S0140-6736(07)60564-9 CrossRefPubMed

68.

Ray, G.T., Pelton, S.I., Klugman, K.P., Strutton, D.R., Moore, M.R.: Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States. Vaccine 27(47), 6483–6494 (2009). doi:10.1016/j.vaccine.2009.08.045 CrossRefPubMed

69.

Ray, G.T., Whitney, C.G., Fireman, B.H., Ciuryla, V., Black, S.B.: Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr. Infect. Dis. J. 25(6), 494–501 (2006). doi:10.1097/01.inf.0000222403.42974.8b CrossRefPubMed

70.

Roche, P.W., Krause, V., Cook, H., Barralet, J., Coleman, D., Sweeny, A., Fielding, J., Giele, C., Gilmour, R., Holland, R., Kampen, R., Brown, M., Gilbert, L., Hogg, G., Murphy, D.: Invasive pneumococcal disease in Australia, 2006. Commun. Dis. Intell. Q Rep. 32(1), 18–30 (2008)PubMed

71.

Jiang, Y., Gauthier, A., Annemans, L., van der Linden, M., Nicolas-Spony, L., Bresse, X.: Cost-effectiveness of vaccinating adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Germany. Expert Rev. Pharmacoecon. Outcomes Res. 12(5), 645–660 (2012). doi:10.1586/erp.12.54 CrossRefPubMed

72.

Diel, M., Laurenz, M., Krause, K., Sprenger, R., Busse, A.: Impact of pneumococcal conjugate vaccines on pneumonia among children in Germany. 31st annual meeting of the European Society of Paediatric Infectious Diseases (ESPID), Milan, Italy, May 28-June 1, Poster A-534-0044-00928 (2013)

73.

Diel, M., Laurenz, M., Krause, K., Sprenger, R., Busse, A.: Impact of pneumococcal conjugate vaccines on acute otitis media among children in Germany. 31st annual meeting of the European Society of Paediatric Infectious Diseases (ESPID), Milan, Italy, May 28–June 1, Poster A-534-0044-00926 (2013)

74.

van der Linden, M., Falkenhorst, G., Perniciaro, S., Imöhl, M.: Effects of infant pneumococcal conjugate vaccination on serotype distribution in invasive pneumococcal disease among children and adults in Germany. PLoS One 10(7), e0131494 (2015). doi:10.1371/journal.pone.0131494 CrossRefPubMedPubMedCentral

75.

Braun, S., Prenzler, A., Mittendorf, T., von der Schulenburg, J.M.: Bewertung von Ressourcenverbräuchen im deutschen Gesundheitswesen aus Sicht der Gesetzlichen Krankenversicherung [Appraisal of valuation of resource use in the German healthcare system from the perspective of the statutory health insurance]. Gesundheitswesen 71, 19–23 (2009)CrossRefPubMed

76.

Institut für das Entgeltsystem im Krankenhaus GmbH: G-DRG-System 2013, Reportbrowser 20011/2013 (2013)

77.

Claes, C., Reinert, R.R., von der Schulenburg, J., Graf, J.-M.: Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects. Eur. J. Health Econ. 10(1), 25–38 (2009). doi:10.1007/s10198-008-0098-1 CrossRefPubMed

78.

National Association of Statutory Health Insurance Physicians: Uniform Value Scale 2013 (2013)

79.

Schulze-Gattermann, H., Illg, A., Schoenermark, M., Lenarz, T., Lesinski-Schiedat, A.: Cost-benefit analysis of pediatric cochlear implantation: German experience. Otol. Neurotol. 23(5), 674–681 (2002)CrossRefPubMed

80.

Federal Employment Agency of Germany (Bundesagentur für Arbeit): Analyse der gemeldeten Arbeitsstellen (2013)

81.

Gesundheitsberichterstattung des Bundes: Arbeitsunfähigkeit bei AOK-Pflichtmitgliedern ohne Rentner (Arbeitsunfähigkeitsfälle, Arbeitsunfähigkeitsfälle je 100.000 Pflichtmitglieder, Arbeitsunfähigkeitstage, Arbeitsunfähigkeitstage je 100.000 Pflichtmitglieder,Tage je Fall). Gliederungsmerkmale: Jahre, Deutschland, Geschlecht, ICD-10 (2008)

82.

Federal Statistical Office of Germany (Statistisches Bundesamt): Bevölkerung, Erwerbstätige, Erwerbslose, Erwerbspersonen, Nichterwerbspersonen: Deutschland, Jahre, Altersgruppen

83.

Federal Statistical Office of Germany (Statistisches Bundesamt): VGR des Bundes - Bruttonationaleinkommen, Volkseinkommen (2013)

84.

Lauertaxe: Arzneimittelpreise (2013)

85.

The EuroQol Group’s International Task Force: Measuring Self-Reported Population Health: An International Perspective based on EQ-5D (2004)

86.

Melegaro, A., Edmunds, W.J.: Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine 22(31–32), 4203–4214 (2004). doi:10.1016/j.vaccine.2004.05.003 CrossRefPubMed

87.

§ 61 Zuzahlungen: Sozialgesetzbuch (SGB) Fünftes Buch (V) - Gesetzliche Krankenversicherung - (SGB V). Artikel 1 G. v. 20.12.1988 BGBl. I S. 2477, 2482; zuletzt geändert durch Artikel 1 G. v. 22.12.2013 BGBl. I S. 4382 (2013)

88.

Pilishvili, T., Lexau, C., Farley, M.M., Hadler, J., Harrison, L.H., Bennett, N.M., Reingold, A., Thomas, A., Schaffner, W., Craig, A.S., Smith, P.J., Beall, B.W., Whitney, C.G., Moore, M.R.: Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J. Infect. Dis. 201(1), 32–41 (2010). doi:10.1086/648593 CrossRefPubMed

89.

Vestrheim, D.F., Høiby, E.A., Bergsaker, M.R., Rønning, K., Aaberge, I.S., Caugant, D.A.: Indirect effect of conjugate pneumococcal vaccination in a 2 + 1 dose schedule. Vaccine 28(10), 2214–2221 (2010). doi:10.1016/j.vaccine.2009.12.054 CrossRefPubMed

90.

Rodenburg, G.D., de Greeff, S.C., Jansen, A.G.C.S., de Melker, H.E., Schouls, L.M., Hak, E., Spanjaard, L., Sanders, E.A.M., van der Ende, A.: Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands. Emerg. Infect. Dis. 16(5), 816–823 (2010). doi:10.3201/eid1605.091223 CrossRefPubMedPubMedCentral

91.

Weinberger, D.M., Malley, R., Lipsitch, M.: Serotype replacement in disease after pneumococcal vaccination. Lancet 378(9807), 1962–1973 (2011). doi:10.1016/S0140-6736(10)62225-8 CrossRefPubMedPubMedCentral

92.

Loo, J.D., Conklin, L., Fleming-Dutra, K.E., Knoll, M.D., Park, D.E., Kirk, J., Goldblatt, D., O’Brien, K.L., Whitney, C.G.: Systematic review of the indirect effect of pneumococcal conjugate vaccine dosing schedules on pneumococcal disease and colonization. Pediatr. Infect. Dis. J. 33(Suppl 2), S161–S171 (2014). doi:10.1097/INF.0000000000000084 CrossRefPubMed

93.

Harboe, Z.B., Dalby, T., Weinberger, D.M., Benfield, T., Mølbak, K., Slotved, H.C., Suppli, C.H., Konradsen, H.B., Valentiner-Branth, P.: Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin. Infect. Dis. 59(8), 1066–1073 (2014). doi:10.1093/cid/ciu524 CrossRefPubMed

94.

Steens, A., Vestrheim, D.F., de Blasio, B.F.: Pneumococcal vaccination in older adults in the era of childhood vaccination: public health insights from a Norwegian statistical prediction study. Epidemics 11, 24–31 (2015). doi:10.1016/j.epidem.2015.01.001 CrossRefPubMed

95.

Rodrigo, C., Bewick, T., Sheppard, C., Greenwood, S., Mckeever, T.M., Trotter, C.L., Slack, M., George, R., Lim, W.S.: Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia. Eur. Respir. J. 45(6), 1632–1641 (2015). doi:10.1183/09031936.00183614 CrossRefPubMed

96.

Moore, M.R., Link-Gelles, R., Schaffner, W., Lynfield, R., Lexau, C., Bennett, N.M., Petit, S., Zansky, S.M., Harrison, L.H., Reingold, A., Miller, L., Scherzinger, K., Thomas, A., Farley, M.M., Zell, E.R., Taylor, T.H., Pondo, T., Rodgers, L., McGee, L., Beall, B., Jorgensen, J.H., Whitney, C.G.: Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA. Analysis of multisite, population-based surveillance. Lancet Infect. Dis. 15(3), 301–309 (2015). doi:10.1016/S1473-3099(14)71081-3 CrossRefPubMedPubMedCentral

97.

Htar, M.T.T., Christopoulou, D., Schmitt, H.-J.: Pneumococcal serotype evolution in Western Europe. BMC Infect. Dis. 15, 419 (2015). doi:10.1186/s12879-015-1147-x CrossRef

98.

Pletz, M.W., von Baum, H., van der Linden, M., Rohde, G., Schütte, H., Suttorp, N., Welte, T.: The burden of pneumococcal pneumonia-experience of the German competence network CAPNETZ. Pneumologie 66(8), 470–475 (2012). doi:10.1055/s-0032-1310103 CrossRefPubMed

99.

Andrews, N.J., Waight, P.A., Burbidge, P., Pearce, E., Roalfe, L., Zancolli, M., Slack, M., Ladhani, S.N., Miller, E., Goldblatt, D.: Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect. Dis 14(9), 839–846 (2014). doi:10.1016/S1473-3099(14)70822-9 CrossRefPubMed

100.

Bonten, M.J., Huijts, S.M., Bolkenbaas, M., Webber, C., Patterson, S., Gault, S., van Werkhoven, C.H., van Deursen, A.M., Sanders, E.A., Verheij, T.J., Patton, M., McDonough, A., Moradoghli-Haftvani, A., Smith, H., Mellelieu, T., Pride, M.W., Crowther, G., Schmoele-Thoma, B., Scott, D.A., Jansen, K.U., Lobatto, R., Oosterman, B., Visser, N., Caspers, E., Smorenburg, A., Emini, E.A., Gruber, W.C., Grobbee, D.E.: Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N. Engl. J. Med. 372(12), 1114–1125 (2015). doi:10.1056/NEJMoa1408544 CrossRefPubMed

101.

van Werkhoven, C.H., Huijts, S.M., Bolkenbaas, M., Webber, C., Schmoele-Thoma, B., Patterson, S.D., Gruber, W., Grobbee, D.E., Bonten, M.: 109913-valent pneumococcal conjugate vaccine efficacy is declining with old age: results from an exploratory analysis of the CAPiTA trial. Open Forum Infect. Dis. 1(Suppl 1), S324–S325 (2014). doi:10.1093/ofid/ofu052.807 CrossRef

102.

Knol, M.J., Wagenvoort, G.H.J., Sanders, E.A.M., Elberse, K., Vlaminckx, B.J., de Melker, H.E., van der Ende, A.: Invasive pneumococcal disease 3 years after Introduction of 10-valent pneumococcal conjugate vaccine, the Netherlands. Emerg. Infect. Dis. 21(11), 2040–2044 (2015). doi:10.3201/eid2111.140780 CrossRefPubMedPubMedCentral

103.

Mangen, M.-J.J., Rozenbaum, M.H., Huijts, S.M., van Werkhoven, C.H., Postma, D.F., van Deursen, A.M.M., van der Ende, A., Grobbee, D.E., Sanders, E.A.M., Sato, R., Verheij, T.J.M., Vissink, C.E., Bonten, M.J.M., de Wit, G.A.: Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands. Eur. Respir. J. 46(5), 1407–1416 (2015). doi:10.1183/13993003.00325-2015 CrossRefPubMedPubMedCentral

104.

Claes, C., von der Schulenburg, J.-M.G.: Gesundheitsökonomische Modellierung eines Szenarios zum Serotypen-Catch-up bei der Impfung gegen Pneumokokken mit PCV13 (Prevenar 13^®) in Deutschland. Pharmacoecon. Ger. Res. Artic. 8(2), 85–95 (2010). doi:10.1007/BF03320767 CrossRef

105.

Choi, Y.H., Jit, M., Gay, N., Andrews, N., Waight, P.A., Melegaro, A., George, R., Miller, E., Borrow, R.: 7-Valent pneumococcal conjugate vaccination in England and Wales: Is it still beneficial despite high levels of serotype replacement? PLoS One 6(10), e26190 (2011). doi:10.1371/journal.pone.0026190 CrossRefPubMedPubMedCentral

106.

Choi, Y.H., Jit, M., Flasche, S., Gay, N., Miller, E., Beall, B.: Mathematical modelling long-term effects of replacing Prevnar7 with Prevnar13 on invasive pneumococcal diseases in England and Wales. PLoS One 7(7), e39927 (2012). doi:10.1371/journal.pone.0039927 CrossRefPubMedPubMedCentral

107.

Farkouh, R.A., Klok, R.M., Postma, M.J., Roberts, C.S., Strutton, D.R.: Cost-effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions. Expert Rev. Vaccines 11(10), 1235–1247 (2012). doi:10.1586/erv.12.99 CrossRefPubMed

Titel: Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany
verfasst von: Alexander Kuhlmann
J.-Matthias Graf von der Schulenburg
Publikationsdatum: 23.02.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: The European Journal of Health Economics / Ausgabe 3/2017
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-016-0770-9

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany

Abstract

Background

Methods

Results

Conclusions

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2017

Analyzing disparity trends for health care insurance coverage among non-elderly adults in the US: evidence from the Behavioral Risk Factor Surveillance System, 1993–2009

The role of time and risk preferences in adherence to physician advice on health behavior change

Disruptive innovation and EU health policy

Cost of diabetic eye, renal and foot complications: a methodological review

Primary health care utilisation and its costs among middle-aged smokers

Economic crisis and suicides in Spain. Socio-demographic and regional variability